BioMason has raised $101.7M across 2 funding rounds.
Biomason has received at least $1.5 million in investment, according to a report from the North Carolina law firm Smith Anderson, which advised on the financing as the company built out its biocement technology.
2 funding rounds, the latest highlighted.
BioMason was founded in 2012, United States.
Celesta Capital, Hartree Partners, Novo Holdings, Martin Marietta Materials. $65M raised, led by 2150.
No filing has been made.
2 dated rounds, newest first.
The routes section explains what is realistically available for a company at this stage.
No. BioMason is a private company; its shares do not trade on a public exchange.
Lead investors for each round are in the funding timeline.
The closest biotechnology peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
